REFERENCES
1. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016;34:1787-94.
2. Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumor Biol 2015;36:4773-6.
3. Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: geographical distribution, mechanism of action and prevention. Oncol Lett 2013;5:1087-92.
4. Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, LoConte NK, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79.
5. Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol 2017;72:626-35.
6. Juarez-Hernandez E, Motola-Kuba D, Chavez-Tapia NC, Uribe M, Barbero Becerra V. Biomarkers in hepatocellular carcinoma: an overview. Expert Rev Gastroenterol Hepatol 2017;11:549-58.
7. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56:1371-83.
8. Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, et al. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 2014;60:995-1001.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Nati Acadof Sci U S A 2008;105:10513-8.
10. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503.
11. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010;52:690-7.
12. Zhang J, Yang Y, Yang T, Liu Y, Li A, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010;103:1215-20.
13. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
14. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836-45.
15. Li D, Liu X, Lin L, Hou J, Li N, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011;286:36677-85.
16. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012;61:278-89.
17. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 2011;140:322-31.
18. Jia YS, Liu HL, Zhuang QS, Xu SQ, Yang ZH, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep 2012;27:1865-72.
19. Wang C, Song B, Song W, Liu J, Sun A, et al. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol 2011;26:1630-7.
20. Li QJ, Zhou L, Yang F, Wang GX, Zheng H, et al. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biol 2012;33:1455-65.
21. Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012;25:156-61.
22. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mole Carcinog 2013;52:297-303.
23. Liu S, Guo W, Shi J, Li N, Yu X, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012;56:389-96.
24. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012;138:153-61.
25. Wang J, Li J, Shen J, Wang C, Yang L, et al. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012;12:227.
26. Wong QWL, Ching AK, Chan AW, Choy KW, To KF, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010;16:867-75.
27. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011;140:1618-28.
28. Xie Y, Yao Q, Butt AM, Guo J, Tian Z, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014;15:1248-55.
29. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012;57:2910-6.
30. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, et al. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 2014;9:47.
31. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012;138:153-61.
32. Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009;14:529-38.
33. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70:9798-807.
34. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010;329:689-93.
35. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007;129:1311-23.
36. Li Y, Wang Z, Shi H, Li H, Li L, et al. HBXIP and LSD1 scaffolded by lncRNA Hotair mediate transcriptional activation by c-Myc. Cancer Res 2016;76:293-304.
37. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, et al. Overexpression of long non-coding RNA Hotair predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011;18:1243-50.
38. Xie H, Ma HW, Zhou DQ. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013;2013:136106.
39. Cui M, Xiao Z, Wang Y, Zheng M, Song T, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res 2015;75:846-57.
40. Du Y, Kong G, You X, Zhang S, Zhang T, et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 2012;287:26302-11.
41. Wang Y, Chen F, Zhao M, Yang Z, Li J, et al. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem 2017;292:15395-407.
42. Zhao J, Greene CM, Gray SG, Lawless MW. Long noncoding RNAs in liver cancer: what we know in 2014. Expert Opin Ther Targets 2014;18:1207-18.
43. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010;5:e9749.
44. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, et al. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer 2011;129:1170-9.
45. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012;55:1799-808.
46. He C, Xu J, Zhang J, Xie D, Ye H, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 2012;43:1425-35.
47. Cai MY, Hou JH, Rao HL, Luo RZ, Li M, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 2011;17:12-20.
48. Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014;9:1-7.
49. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
50. Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res 2016;46:E130-5.
51. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
52. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
53. Fu Y, Xu X, Huang D, Cui D, Liu L, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial. EBioMedicine 2017;24:56-63.
54. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012;13:817-26.
55. Abdel Wahab AHA, El-Halawany MS, Emam AA, Elfiky A, Abd Elmageed ZY. Identification of circulating protein biomarkers in patients with hepatocellular carcinoma concomitantly infected with chronic hepatitis C virus. Biomarkers 2017;22:621-8.
56. Zhang S, Jiang K, Zhang Q, Guo K, Liu Y. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index. Glycoconj J 2015;32:119-25.
57. Zhang W, Chen J, Wu M, Zhang X, Zhang M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology 2017;66:398-415.
58. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;351:351.
59. Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLos One 2014;9:e95870.
60. Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 2016;64:S117-S131.
61. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006;147:58-66.
62. Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol Med 2014;11:182-90.
63. Gao Y, Feng J, Yang G, Zhang S, Liu Y, et al. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology 2017;66:1413-29.
64. Zhang H, Wu LY, Zhang S, Qiu LY, Li N, et al. Anti-Hepatitis B virus X protein in sera is one of the markers of development of liver cirrhosis and liver cancer mediated by HBV. J Biomed Biotechnol 2009;2009:289068.
65. Zhang S, Gao S, Zhao M, Liu Y, Bu Y, et al. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett 2017;392:94-104.
66. Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, et al. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1181252.
67. Sun J, Jiang W, Tian D, Guo Q, Shen Z. Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression. Onco Targets Ther 2018;11:8227-37.
68. Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2018; doi: 10.1007/s12094-018-1975-4.
69. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
70. Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev 2018;68:16-24.
71. Best J, Schotten C, Lohmann G, Gerken G, Dechene A. Tivantinib for the treatment of hepatocellular carcinoma. Expert Opin Pharmacother 2017;18:727-33.
72. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology 2017;52:512-9.
73. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
74. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8.
75. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. J Clin Oncol 2018;36.
76. Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36.
77. Zhu AX, Ryoo BY, Yen CJ, Kudo M, Poon RTP, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated alpha-fetoprotein (AFP) from the randomized phase III REACH study. J Clin Oncol 2015;33.
78. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
79. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70.
80. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78 Suppl 1:154-66.
